All In Biotech

Drug Trial Radar · NCT07940166

A Study of HRS-8046 in Patients With Advanced Solid Tumors: Safety, Tolerability, and Pharmacokinetics

A Phase I Clinical Study of the Safety, Tolerability, and Pharmacokinetics of HRS-8046 in Participants With Solid Tumors

Last checked: Nov 20, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

175

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Jan 2029

Study completion Apr 2029

Sponsor

Sponsor type
Industry
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being conducted to evaluate the efficacy and safety of HRS-8046 in patients with solid tumors, and to determine the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of HRS-8046.

Conditions

  • Solid Tumor

Interventions

  • HRS-8046 TabletDrug

    HRS-8046 tablet.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs)Time frame: Approximately 2 years.
  2. Maximum tolerated dose (MTD)Time frame: Approximately 1 year.
  3. Recommended Phase II Dose (RP2D)Time frame: Approximately 2 years.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital with Nanjing Medical University (Jiangsu Province Hospital)

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Naval Medical University (Shanghai Changhai Hospital)

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.